Pfizer Inc.PFENYSE

Overview Intelligence Charts News Fundamentals

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

20 analysts·High coverage

30%

Rating Distribution

Strong Buy

00%

Buy

630%

Hold

1470%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Price is near analyst consensus — limited near-term upside expected.

Bear Case

$24.00

-10%

Consensus

$27.36

+2%

Bull Case

$35.00

+31%

Price Range20 analysts

Low

Consensus

High

$24.00

$35.00

Current Target

Current Price

$26.70

Upside to Target

$0.66

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$2.96(15 analysts)

P/E20x

Current: 19.6x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-3.74%

EPS-4.37%

FY2028

Rev-6.97%

EPS-13.56%

FY2029

Rev-5.00%

EPS-9.71%

Earnings Surprises

Beat rate:100%(12/12 quarters)

Avg surprise:+47.3%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 24, 2026RBC Capital

RBC Capital Starts Pfizer (PFE) at Underperform

Target:$25.00

-7.9%from $27.14

Feb 19, 2026Barclays

Pfizer initiated with an Underweight at Barclays

Target:$25.00

-6.9%from $26.86

Feb 12, 2026Daiwa

Pfizer downgraded to Neutral from Outperform at Daiwa

Target:$27.00

-2.6%from $27.73

Jan 27, 2026Cantor Fitzgerald

Pfizer price target raised to $27 from $24 at Cantor Fitzgerald

Target:$27.00

+4.3%from $25.88

Jan 6, 2026UBS

Pfizer assumed with a Neutral at UBS

Target:$25.00

-1.7%from $25.43

Dec 17, 2025Wolfe Research

Pfizer (PFE) PT Lowered to $24 at Wolfe Research

Target:$24.00

-6.0%from $25.53

Dec 12, 2025Morgan Stanley

Pfizer price target lowered to $28 from $32 at Morgan Stanley

Target:$28.00

+8.1%from $25.89

Dec 10, 2025HSBC

Pfizer price target raised to $29 from $28 at HSBC

Target:$29.00

+14.5%from $25.33

Nov 24, 2025Guggenheim

Pfizer price target raised to $35 from $33 at Guggenheim

Target:$35.00

+39.1%from $25.17

Nov 5, 2025Goldman Sachs

Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'

Target:$26.00

+7.3%from $24.23

Oct 31, 2025Bernstein

Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera

Target:$30.00

+22.7%from $24.45

Oct 10, 2025Morgan Stanley

Pfizer price target lowered to $32 from $33 at Morgan Stanley

Target:$32.00

+26.8%from $25.24

Oct 1, 2025UBS

Pfizer drug pricing deal 'mostly performative,' says BofA

Target:$28.00

+3.1%from $27.16

Apr 22, 2025Cantor Fitzgerald

Pfizer initiated with a Neutral at Cantor Fitzgerald

Target:$24.00

+6.5%from $22.53

Dec 18, 2024Truist Financial

Pfizer price target lowered to $32 from $36 at Truist

Target:$32.00

+23.6%from $25.89

Oct 30, 2024Goldman Sachs

Pfizer (PFE) PT Raised to $33 at Goldman Sachs

Target:$33.00

+16.0%from $28.46

Oct 17, 2024Bernstein

Pfizer initiated with a Market Perform at Bernstein

Target:$32.00

+7.9%from $29.67

Sep 25, 2024Barclays

Pfizer withdrawal raises business development questions, says Barclays

Target:$32.00

+10.6%from $28.93

Aug 7, 2024Daiwa

Daiwa Securities Upgrades Pfizer (PFE) to Outperform (2)

Target:$34.00

+17.9%from $28.85

Jul 31, 2024Wells Fargo

Pfizer price target raised to $30 from $28 at Wells Fargo

Target:$30.00

-4.4%from $31.39

Jul 31, 2024Goldman Sachs

Pfizer (PFE) PT Raised to $34 at Goldman Sachs

Target:$34.00

+8.3%from $31.39

Jul 30, 2024Guggenheim

Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Target:$36.00

+17.2%from $30.72

Jul 10, 2024Barclays

Pfizer price target raised to $30 from $28 at Barclays

Target:$30.00

+8.2%from $27.72

May 22, 2024BMO Capital

Pfizer cost reduction program a positive for the shares, says BMO

Target:$36.00

+21.6%from $29.60

Feb 14, 2024Cantor Fitzgerald

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

Target:$45.00

+66.9%from $26.97

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance